Patents Examined by Lei Yao
  • Patent number: 10925948
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 23, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Claudia Wagner, Julia Leibold, Colette Song
  • Patent number: 10925947
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 23, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 10925971
    Abstract: Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 23, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Marcus Kelly, Jessica Kirshner, Gavin Thurston
  • Patent number: 10919972
    Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
  • Patent number: 10921325
    Abstract: The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anticancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent.
    Type: Grant
    Filed: May 7, 2016
    Date of Patent: February 16, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: You-Sun Kim, Gi Bang Koo
  • Patent number: 10913983
    Abstract: Disclosed are targeted anti-proliferative approaches for breast cancer utilizing CDK7 inhibitors having efficacy in multiple subtypes of breast cancer, including but without limitation to ER-positive, HER2-positive and Triple Negative Breast Cancer. Methods utilize CDK7 inhibitors alone as well in conjunction with EGFR inhibitors, which provides synergistic anti-proliferative effects on breast cancer cells across a broad spectrum of breast cancer subtypes. Methods for determining sensitivity of breast cancer subtypes to CDK7 inhibitors based upon CITED2 expression levels are also described.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 9, 2021
    Assignee: University of South Carolina
    Inventors: Eugenia Broude, Martina McDermott
  • Patent number: 10906988
    Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: February 2, 2021
    Assignee: BioNTech Research and Development, Inc.
    Inventors: Wolfgang Scholz, Ritsuko Sawada
  • Patent number: 10899812
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Annika Sonntag, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Colette Song
  • Patent number: 10898560
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Claudia Wagner, Julia Leibold, Colette Song
  • Patent number: 10898559
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Claudia Wagner, Julia Leibold, Colette Song
  • Patent number: 10898570
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Patent number: 10899813
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Annika Sonntag, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Colette Song
  • Patent number: 10899814
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Annika Sonntag, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh, Colette Song
  • Patent number: 10894036
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 19, 2021
    Assignee: Celgene International II Sarl
    Inventors: Mohit Trikha, Ann MacLaren, Nancy Levin
  • Patent number: 10888609
    Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Michael Olin
  • Patent number: 10882918
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 5, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Joaquin Arribas, Rocio Vicario
  • Patent number: 10874713
    Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: December 29, 2020
    Assignee: IMMUTEP S.A.S.
    Inventors: Frederic Triebel, Chrystelle Brignone
  • Patent number: 10877039
    Abstract: The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1?, TGF?1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: December 29, 2020
    Assignee: VISION TECH BIO PTY. LTD.
    Inventors: Leah Jane Cosgrove, Bruce Tabor, Antony Wilks Burgess, Edouard Collins Nice
  • Patent number: 10870708
    Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 22, 2020
    Assignee: University of Leicester
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Thomas Dudler, Larry Tjoelker
  • Patent number: 10869917
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: December 22, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh